{"filing":{"accession_number":"0001140361-26-032650","cik":"0001472091","ticker":"PDSB","company_name":"PDS Biotechnology Corp","form":"8-K","filing_date":"2026-08-13","report_date":"2026-08-13","primary_document":"ef20080122_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1472091/000114036126032650/ef20080122_8k.htm"},"events":[{"id":27561,"run_id":25129,"accession_number":"0001140361-26-032650","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"PDS Biotechnology issued a press release on August 13, 2026 announcing financial results for the quarter ended June 30, 2026, including net loss of $9.8 million, operating expenses, interest expense, and cash balance of $5.6 million. The filing includes condensed consolidated statements of operations and selected balance sheet data, which are standard components of a quarterly earnings disclosure under Item 2.02.","company_name":"PDS Biotechnology Corp","ticker":"PDSB","filing_date":"2026-08-13","form":"8-K","submitted_at":null,"items":[{"id":29144,"accession_number":"0001140361-26-032650","item_number":"2.02","item_title":null,"event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"PDS Biotechnology issued a press release on August 13, 2026 announcing financial results for the quarter ended June 30, 2026, including net loss of $9.8 million, operating expenses, interest expense, and cash balance of $5.6 million. The filing includes condensed consolidated statements of operations and selected balance sheet data, which are standard components of a quarterly earnings disclosure under Item 2.02.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-13T12:36:58.271414+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":29144,"accession_number":"0001140361-26-032650","item_number":"2.02","item_title":null,"event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"PDS Biotechnology issued a press release on August 13, 2026 announcing financial results for the quarter ended June 30, 2026, including net loss of $9.8 million, operating expenses, interest expense, and cash balance of $5.6 million. The filing includes condensed consolidated statements of operations and selected balance sheet data, which are standard components of a quarterly earnings disclosure under Item 2.02.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-13T12:36:58.271414+00:00","company_name":"PDS Biotechnology Corp","ticker":"PDSB","filing_date":"2026-08-13"}]}